What Is Humanin? Benefits, Research & Safety
A mitochondrial-derived peptide with cytoprotective and anti-apoptotic properties, researched for neuroprotection, metabolic regulation, and ageing.
UK summary: Not a licensed UK medicine. Mitochondrial-derived peptide investigated for neuroprotection and longevity. All studies are preclinical or small observational; no human therapeutic use.
Quick Facts
Overview
Humanin — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Not a licensed UK medicine. Mitochondrial-derived peptide investigated for neuroprotection and longevity. All studies are preclinical or small observational; no human therapeutic use.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Not licensed for any indication. Research compound only.
- EU: Not approved for human use.
- Notes: Humanin is a research peptide with no regulatory approvals anywhere. All studies are preclinical or observational. Products available are from research chemical suppliers and not intended for human use.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Reverses Alzheimer's disease.
- Extends human lifespan.
- Treats long COVID and chronic fatigue.
- Restores mitochondrial function in healthy adults.
07Common internet claims
- Marketed in longevity stacks alongside MOTS-c and SS-31.
- Sold by online retailers as research-only injectable.
- Promoted on biohacker podcasts for mitochondrial health.
08Claim vs evidence
09Safety uncertainty score
Limited human safety data; meaningful uncertainty about rare or long-term effects.
10Known adverse signals
- Essentially no human safety data.
- Injection-site reactions reported anecdotally.
- Unknown chronic effects of supraphysiological humanin signalling.
- Theoretical interactions with apoptosis-related drugs (chemotherapy).
11Drug-interaction uncertainty
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
13UK legal position
Not licensed for any indication. Research compound only.
14EU legal position
Not approved for human use.
15What this page cannot tell you
- Whether a UK-purchased vial contains humanin at the labelled concentration.
- Whether the preclinical neuroprotection translates to human Alzheimer's prevention.
- Long-term consequences of exogenous mitochondrial-derived peptide signalling.
- Whether it interferes with apoptosis pathways relevant to cancer surveillance.
16Last reviewed
17Citation quality score
18Research gaps
- No registered Phase 1 trials in humans for any indication.
- Pharmacokinetic data in humans absent.
- Long-term safety unstudied.
19Safer alternatives / established care pathways
- Evidence-based longevity interventions: exercise, sleep, Mediterranean diet, smoking cessation.
- NHS memory clinic referral for genuine cognitive concerns; licensed Alzheimer's medications under specialist care.
- Routine cancer-screening uptake — the highest-impact longevity intervention available.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Humanin a licensed UK medicine?
- What licensed treatments exist for the cognitive / longevity concern I'm raising?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Neuroprotection against Alzheimer's-related toxicity
- 2Anti-apoptotic effects in multiple cell types
- 3Enhanced insulin sensitivity in animal models
- 4Cardiovascular protection (reduced atherosclerosis in mice)
- 5Reduced oxidative stress and mitochondrial dysfunction
- 6Potential anti-ageing effects (correlates with longevity)
- 7Protection against ischaemia-reperfusion injury
Claim vs Evidence
How popular claims about Humanin stack up against the current research, graded using our public evidence grading methodology.
Theoretical Dosing & Protocols
| Theoretical Dosage | Research only; no established human dosing |
| Frequency | Variable in preclinical studies |
| Duration | Research protocols vary |
| Notes | Humanin and its analogues (HNG) are research compounds only. No human clinical trials for therapeutic use have been completed. Most data comes from cell culture and animal studies. Not available as a pharmaceutical product. |
Administration Routes
Routes studied in research settings (educational only):
- Intraperitoneal injection (animal studies)
- Intravenous (preclinical research)
- Intranasal (experimental)
| Half-Life | Stability |
|---|---|
| Short in circulation; synthetic analogues have improved stability | Native humanin has limited stability; lyophilised powder stored at -20°C |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Limited human data available
- Generally well tolerated in animal studies
Rare Risks & Concerns
- Unknown long-term effects in humans
- Theoretical concerns about anti-apoptotic effects on tumour cells
- Insufficient safety data for human use
Contraindications
- Not approved for human use
- Active malignancy (theoretical concern due to anti-apoptotic mechanism)
- Pregnancy and breastfeeding
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed for any indication. Research compound only.
🇪🇺 European Union
Not approved for human use.
Clinical Studies Summary
Redox-sensitive miRNAs and Humanin could mediate effects of exercise and astaxanthin on oxidative stress and inflammation in type 2 diabetes.
This study was also registered in Iranian Registry of Clinical Trials (IRCT20230225057524N1). Consent for publication: Not applicable.
Neuron-derived extracellular vesicles in blood reveal effects of exercise in Alzheimer's disease.
Findings suggest that the cognitive benefits of exercise could be mediated by the upregulation of neuroprotective factors in NDEVs. Additionally, our results indicate that AD subjects carrying APOE ε4 are more responsive to the neuroprotective effects of physical activity.
Mitochondria‑derived peptides: Promising microproteins in cardiovascular diseases (Review).
It is necessary to improve drug delivery systems to enhance the bioavailability of MDPs. Moreover, integrating basic research with clinical trials is essential to bridge the gap between experimental findings and clinical applications.
Mitochondrial-Derived Peptides: Implication in the Therapy of Neurodegenerative Diseases.
Ethical Approval: Not applicable. Informed Consent: Not applicable.
Mitochondrial-derived peptides in cardiovascular disease: Novel insights and therapeutic opportunities.
We also provide insights into the current advancements in clinical research related to the utilization of MDPs in the treatment of CVDs. This review may provide valuable information with MDPs for CVD diagnosis and treatment.
Mitochondrial-derived peptides: Antidiabetic functions and evolutionary perspectives.
MDPs attenuate disease pathology including Type 1 diabetes (T1D), Type 2 diabetes (T2D), gestational diabetes, Alzheimer's disease (AD), cardiovascular diseases, prostate cancer, and macular degeneration. The current review will focus on the MDP regulation of T2D, T1D, and gestational diabetes along with an emphasis on the evolutionary pressures for conservation of the amino acid sequences of MDPs.
Registered Trials & Regulatory Status
1 of 1 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.
Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal Transplantation
Status: Recruiting · 68 participants · University of Gaziantep
Conditions: Kidney Disease, End-Stage, Kidney Transplant, Kidney
Clinical Value of Plasma Humanin in Acute Kidney Injury
Status: Unknown · 60 participants · Guangdong Provincial People's Hospital
Conditions: Acute Kidney Injury
Humanin Isoforms in Cardiac Muscle and Blood Plasma and Major Complications After Cardiac Operation
Status: Completed · 106 participants · University of Tartu
Conditions: Myocardial Ischemia, Coronary Artery Bypass Surgery
Adverse event reports (FDA FAERS)
Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.
Source: ClinicalTrials.gov and openFDA. Updated automatically.
Looking for Humanin?
Source research-grade Humanin from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Humanin
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Humanin a licensed UK medicine?
- What licensed treatments exist for the cognitive / longevity concern I'm raising?
UK regulatory & safety context
Related Research Guides
Related Peptides
GHK-Cu
A naturally occurring copper-binding tripeptide researched for its roles in wound healing, skin regeneration, anti-ageing, and tissue remodelling.
Learn moreEpitalon
A synthetic tetrapeptide based on epithalamin, researched for its potential effects on telomerase activation and biological ageing.
Learn moreMOTS-c
A mitochondrial-derived peptide that regulates metabolic homeostasis and exercise adaptations, representing a novel class of signalling molecules.
Learn moreSS-31
A mitochondria-targeted tetrapeptide in clinical trials for heart failure, mitochondrial myopathy, and age-related mitochondrial dysfunction.
Learn more